Dendreon Corp: All Recent News

• All recent news
• Earnings news

Cel-Sci's History of Disappearing Drugs: BioBuzz 11/24/2009

Will the company's flu drug last longer than its other fly-by-night projects? At TheStreet.com

BioCryst Bull Blames Conspiracy for Stock's Fall: BioBuzz 11/24/2009

Hedge funds, Wall Street, SEC and FDA out to hurt maker of flu drug, newsletter writer claims. At TheStreet.com

Market Report -- In Play (DNDN) 11/20/2009

Dendreon holds test of 50-day SMA (27.86) and recovers 28-level Stock tested the average for the second straight day, and has held it so far in morning trading... Briefing.com

Dendreon's Provenge gets FDA review date 11/20/2009

SEATTLE (AP) - Biotechnology company Dendreon Corp. said Friday the Food and Drug Administration will make a regulatory decision on the potential prostate cancer vaccine Provenge by May 1. Associated Press

UPDATE 1-FDA says Dendreon's drug application is complete 11/20/2009

... At Thomson Reuters

Market Report -- In Play (DNDN) 11/20/2009

Dendreon receives FDA acknowledgement of complete response Co announces that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the amended Biologics License Application... Briefing.com

Dendreon Receives FDA Acknowledgement of Complete Response 11/20/2009

-- PDUFA Date Assigned as May 1, 2010 --SEATTLE, Nov. 20 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. Food and Drug Administration (FDA) provided... PR Newswire

Biotech Stock Mailbag: FDA Playbook 11/20/2009

Smart drug and biotech companies keep the FDA abreast of their clinical trial program throughout the long drug-development process. At TheStreet.com

Market Report -- In Play (DNDN) 11/19/2009

Dendreon comes in to test its 50-day SMA at 27.77 &nbsp... Briefing.com

This Is Why You're Not Making Money in the Market 11/17/2009

If you're feeling encouraged by the rally, maybe it's time to take a deep breath and slow back down. At Motley Fool

($) Mixed Start 11/17/2009

So far, it is just some mild consolidation after a big day yesterday. At TheStreet.com

Market Report -- Short Stories (DNDN) 11/12/2009

Dendreon: 3Q09 report highlights busy preparations for Provenge launch- Leerink Swann . Leerink Swann notes DNDN's higher-than-estimated reported loss in 3Q:09 was contributed by a large non-cash... Briefing.com

Earnings roundup: Applied Materials, Macy's 11/11/2009

(AP) - Among the earnings stories for Wednesday, Nov. 11, from AP Financial News:... Associated Press

Dendreon 3Q loss widens on expenses, charge 11/11/2009

SEATTLE (AP) - Dendreon Corp., which is developing the prostate cancer drug Provenge, said Wednesday its third-quarter loss widened on a boost in operating expenses and costs to cover the value of warrants to buy its shares. Associated Press

Dendreon Reports Third Quarter 2009 Financial Results and... 11/11/2009

-- Conference Call to be Hosted Today at 4:30 p.m. EST --SEATTLE, Nov. 11 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the quarter ended September 30,... PR Newswire

More News

Market Report

News by Symbol

Today's Investing Articles

Breaking News

News by Topic

News by Industry

MSNBC News

MSN Money

Search MSN Money

Message Boards

Site Status